The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ponasenko O.I.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazova T.Yu.

National Medical Research Center of Oncology named after N.N. Petrov;
North-Western State Medical University named after I.I. Mechnikov

Klimenko V.V.

National Medical Research Center of Oncology named after N.N. Petrov

Abdullaeva Sh.R.

National Medical Research Center of Oncology named after N.N. Petrov

Sevostyanova T.I.

National Medical Research Center of Oncology named after N.N. Petrov

Kobysheva M.S.

National Medical Research Center of Oncology named after N.N. Petrov

Filatova L.V.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazov V.V.

National Medical Research Center of Oncology named after N.N. Petrov;
Pavlov First Saint Petersburg State Medical University

Kasparov B.S.

National Medical Research Center of Oncology named after N.N. Petrov;
Saint Petersburg State Pediatric Medical University

Krivorotko P.V.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazov V.F.

National Medical Research Center of Oncology named after N.N. Petrov

Adherence to breast cancer treatment: positions of patient and doctor

Authors:

Ponasenko O.I., Semiglazova T.Yu., Klimenko V.V., Abdullaeva Sh.R., Sevostyanova T.I., Kobysheva M.S., Filatova L.V., Semiglazov V.V., Kasparov B.S., Krivorotko P.V., Semiglazov V.F.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2025;47(4): 74‑83

DOI: 10.17116/medtech20254704174

Read: 171 times

Buy for 300₽
Contact the author
Table of contents

ADHERENCE TO BREAST CANCER TREATMENT: POSITIONS OF PATIENT AND DOCTOR
ADHERENCE TO BREAST CANCER TREATMENT: POSITIONS OF PATIENT AND DOCTOR

To cite this article:

Ponasenko OI, Semiglazova TYu, Klimenko VV, et al. . Adherence to breast cancer treatment: positions of patient and doctor. Medical Technologies. Assessment and Choice. 2025;47(4):74‑83. (In Russ.)
https://doi.org/10.17116/medtech20254704174

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Changes in diagnosis-related group payment model in the Russian Fede­ration in 2025. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):18-30
Approaches to the digi­tization of clinical guidelines. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):39-47
Review of the main provisions of the upda­ted clinical reco­mmendations “Noise-induced hearing loss”. Russian Bulletin of Otorhinolaryngology. 2025;(2):88-93
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Clinical Deci­sions in the Abse­nce of Evidence: Expert’s Panel Reco­mmendations for the Mana­gement of Chro­nic Venous Disease and Supe­rficial Thro­mbophlebitis. Journal of Venous Diso­rders. 2025;(2):126-140
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Unre­solved questions of recu­rrent implantation failure. Russian Journal of Human Reproduction. 2025;(3):42-47
Reso­lution of the exte­nded meeting of the Presidium and committees of the Russian Asso­ciation for the Study of Pain (RASP) “The role of central muscle rela­xants in the treatment of non-specific low back pain”. Russian Journal of Pain. 2025;(2):91-91
Community-acquired pneumonia in adults. Clinical guidelines 2024 (short version). Journal of Respiratory Medi­cine. 2025;(3):6-18
Controversial issues of neoadjuvant hormone therapy for early lumi­nal HER2-negative breast cancer in postmenopausal patients. P.A. Herzen Journal of Onco­logy. 2025;(5):89-93
Abstract:

The issue of patient adherence to treatment and compliance of medical practice with existing standards remains relevant in all areas of medicine. This aspect is the most studied in relation to the treatment of chronic diseases. Adjuvant hormone therapy for breast cancer is one the leading directions in oncology. Patients who adhere to the doctor’s recommendations are more likely to achieve their treatment goals. The applied methods can be divided into two main groups: direct and indirect. Each of them has its own limitations, and the choice of a specific method depends on the study objectives. Doctors who adhere to the established practices ensure consistent quality of the provided medical care. Questionnaire survey of specialists about the regulations included in official guidelines is one of the most common methods for assessment of doctors’ adherence to treatment standards. This method is not perfect because it is subjective, but there are no alternatives. Effective implementation of medical advances in clinical practice depends directly on the degree of adherence of doctors to up-to-date guidelines and patients — to specialist assignments.

Keywords:

adherence of patients
adherence of doctors
questionnaires
early breast cancer
adjuvant therapy
hormone therapy
methods of adherence assessment
clinical guidelines

Authors:

Ponasenko O.I.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazova T.Yu.

National Medical Research Center of Oncology named after N.N. Petrov;
North-Western State Medical University named after I.I. Mechnikov

Klimenko V.V.

National Medical Research Center of Oncology named after N.N. Petrov

Abdullaeva Sh.R.

National Medical Research Center of Oncology named after N.N. Petrov

Sevostyanova T.I.

National Medical Research Center of Oncology named after N.N. Petrov

Kobysheva M.S.

National Medical Research Center of Oncology named after N.N. Petrov

Filatova L.V.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazov V.V.

National Medical Research Center of Oncology named after N.N. Petrov;
Pavlov First Saint Petersburg State Medical University

Kasparov B.S.

National Medical Research Center of Oncology named after N.N. Petrov;
Saint Petersburg State Pediatric Medical University

Krivorotko P.V.

National Medical Research Center of Oncology named after N.N. Petrov

Semiglazov V.F.

National Medical Research Center of Oncology named after N.N. Petrov

Received:

16.03.2025

Accepted:

14.07.2025

Close metadata

References:

  1. Food and Drug Administration. Novel Drug Approvals for 2024. Accessed September 15, 2025. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
  2. Semiglazova TY, Ponasenko OI, Lyashchenko VA, et al. Late complications of breast cancer treatment: osteoporosis, cardiotoxicity, fertility disorders (Part 2). Voprosy Onkologii. 2025;71(1):17-34. (In Russ). https://doi.org/10.37469/0507-3758-2025-71-1-OF-2029
  3. Mir TH. Adherence Versus Compliance. HCA Healthcare Journal of Medicine. 2023;4(2):219-220.  https://doi.org/10.36518/2689-0216.1513
  4. Oxford Learner’s Dictionaries. Accessed March 4, 2025. https://www.oxfordlearnersdictionaries.com/
  5. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Medicine and Pharmacy Reports. 2019;92(2):117-122.  https://doi.org/10.15386/mpr-1201
  6. Ionov MV, Emelyanov IV, Konradi AO. Direct methods for assessing adherence to antihypertensive therapy: witnessed intake and therapeutic drug monitoring. Racional`naya farmakoterapiya v kardiologii. 2025;21(3):234-243. (In Russ). https://doi.org/10.20996/1819-6446-2025-3192
  7. Nikolaev NA, Martynov AI. Skirdenko YuP, et al. Priverzhennost` lecheniyu. Rossijskoe nacional`noe rukovodstvo. Setevoe nauchnoe izdanie; 2022. Accessed September 23, 2025. (In Russ.). https://rnmot.org/video/repository/priverghennosty_lecheniyu_rosnacruk_2022_c99e5d15.pdf
  8. World Health Organization. Adherence to long-term therapies. Evidence for action. 2003. Accessed March 4, 2025. https://iris.who.int/handle/10665/42682
  9. Rosenberg SM, Petrie KJ, Stanton AL, et al. Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. Journal of the National Cancer Institute. 2020;112(5):443-465.  https://doi.org/10.1093/jnci/djz244
  10. Dang TH, Forkan ARM, Wickramasinghe N, et al. Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews. JMIR Cancer. 2022;8(2):e34833. https://doi.org/10.2196/34833
  11. Mullangi S, Chen X, Pham T, et al. Association of patient, physician, and practice-level factors with uptake of payer-led oncology clinical pathways. JAMA Network Open. 2023;6(5):e2312461. https://doi.org/10.1001/jamanetworkopen.2023.12461
  12. Leonhardt CS, Lanzenberger L, Puehringer R, et al. Evidence-based cancer care: assessing guideline adherence of multidisciplinary tumor board recommendations for breast and colorectal cancer in a non-academic medical center. Journal of Cancer Research and Clinical Oncology. 2024;151(1):4.  https://doi.org/10.1007/s00432-024-06049-x
  13. Bierbaum M, Rapport F, Arnolda G, et al. Clinical practice guideline adherence in oncology: A qualitative study of insights from clinicians in Australia. PloS One. 2022;17(12):e0279116. https://doi.org/10.1371/journal.pone.0279116
  14. Gori S, Fabi A, Angiolini C, et al. Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice. Frontiers in Oncology. 2025;15:1501667. https://doi.org/10.3389/fonc.2025.1501667
  15. Adegboyega TO, Landercasper J, Linebarger JH, et al. Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reporting. Journal of the National Comprehensive Cancer Network. 2015;13(2):177-183.  https://doi.org/10.6004/jnccn.2015.0026
  16. Carbonara L, Casale G, De Marinis MG, et al. Adherence to ESMO guidelines on cancer pain management and their applicability to specialist palliative care centers: An observational, prospective, and multicenter study. Pain Practice. 2024. Online ahead of print. https://doi.org/10.1111/papr.13418
  17. Bergerot CD, Soto-Perez-de-Celis E, Thompson C, et al. Navigating challenges in palliative care: A survey on ASCO guideline adherence among health care providers in low- and middle-income countries. JCO Global Oncology. 2025;11:e2400625. https://doi.org/10.1200/GO.24.00625
  18. Pearl D, Wilkinson AN. Guidelines unmet: Assessing gaps in breast cancer survivorship care. Women’s Health. 2024;20:17455057241306809. https://doi.org/10.1177/17455057241306809
  19. Sabah J, Menoux I, Eberst L, et al. Variability of treatment of locally advanced cervical cancer: How French multidisciplinary teams follow European guidelines? European Journal of Surgical Oncology. 2024;50(6):108281. https://doi.org/10.1016/j.ejso.2024.108281
  20. Gao P, You L, Wu D, et al. Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient preference and adherence. 2018;12:887-897.  https://doi.org/10.2147/PPA.S167004
  21. Cahir C, Barron TI, Sharp L, Bennett K. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I—III breast cancer? Cancer Causes and Control: CCC. 2017;28(3):215-225.  https://doi.org/10.1007/s10552-017-0851-9
  22. Farias AJ, Wu WH, Du XL. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data. BMC Cancer. 2018;18(1):1214. https://doi.org/10.1186/s12885-018-5121-z
  23. Wulaningsih W, Garmo H, Ahlgren J, et al. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Research and Treatment. 2018;172(1):167-177.  https://doi.org/10.1007/s10549-018-4890-z
  24. Sella T, Chodick G. Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel. Breast Care (Basel, Switzerland). 2020;15(1):45-53.  https://doi.org/10.1159/000500318
  25. Blanchette PS, Lam M, Richard L, et al. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast Cancer Research and Treatment. 2020;179(1):217-227.  https://doi.org/10.1007/s10549-019-05430-6
  26. Cavazza M, Banks H, Ercolanoni M, et al. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. Breast Cancer Research and Treatment. 2020;183(1):189-199.  https://doi.org/10.1007/s10549-020-05748-6
  27. Lambert-Côté L, Bouhnik AD, Bendiane MK, et al. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Research and Treatment. 2020;180(3):777-790.  https://doi.org/10.1007/s10549-020-05549-x
  28. Lailler G, Memoli V, Le Bihan Benjamin C, et al. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data. Clinical Breast Cancer. 2021;21(4):e415-e426. https://doi.org/10.1016/j.clbc.2021.01.007
  29. Zheng D, Thomas J, 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Research and Treatment. 2023;201(1):89-104.  https://doi.org/10.1007/s10549-023-06992-2
  30. Woolpert KM, Schmidt JA, Ahern TP, et al. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients. Breast Cancer Research: BCR. 2024;26(1):59.  https://doi.org/10.1186/s13058-024-01819-4
  31. De Jong A, Von Wachenfeldt A, Nyström L, Andersson A. Adherence to adjuvant endocrine therapy after breast cancer in Sweden — a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. Acta Oncologica. 2024;63:901-908.  https://doi.org/10.2340/1651-226X.2024.40575
  32. Zeng E, He W, Sjölander A, et al. Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis. Journal of the National Cancer Institute. 2024;116(6):920-928.  https://doi.org/10.1093/jnci/djae061
  33. Moya JJ, Moazzez A, Ozao-Choy JJ, Dauphine C. Patients with invasive breast cancer who refuse treatment: An analysis of associated factors and impact on survival. American Surgeon. 2021;87(10):1627-1632. https://doi.org/10.1177/00031348211024170
  34. Wang X, Lian Z, Wu Q, et al. Refusal of treatment among HER2-positive breast cancer patients in China: a retrospective analysis. Frontiers in Public Health. 2024;11:1305544. https://doi.org/10.3389/fpubh.2023.1305544
  35. Neugut AI, Hillyer GC, Kushi LH, et al. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer. 2014;21(6):780-785.  https://doi.org/10.1007/s12282-014-0543-1
  36. Bhattacharya M, Liu B, Kurian AW, et al. Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer. Breast Cancer Research and Treatment. 2025;210(2):347-354.  https://doi.org/10.1007/s10549-024-07570-w
  37. Ganna S, Rahimi S, Lu A, et al. Interventions to improve oral endocrine therapy adherence in breast cancer patients. Journal of Cancer Survivorship: Research and Practice. 2025;19(3):930-939.  https://doi.org/10.1007/s11764-023-01513-y
  38. Bright EE, Finkelstein LB, Nealis MS, et al. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence among Breast Cancer Survivors. Journal of Clinical Oncology. 2023;41(28):4548-4561. https://doi.org/10.1200/JCO.23.00697
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.